BTIG initiates Campbell’s stock coverage with neutral rating By Investing.com

BTIG initiated Campbell’s (CPB) at Neutral as the stock trades near its 30-year low P/E of about 10x, but the firm sees the discount as justified by limited near-term sales, profit, and EPS growth potential and an already levered balance sheet. The article also notes a recent earnings miss, with Q2 fiscal 2026 adjusted EPS of $0.51 versus $0.54 BofA and $0.57 consensus, which has triggered multiple target cuts from TD Cowen, BofA, RBC, Evercore ISI, and Bernstein SocGen. Shares are down 54% over the past year and at a 52-week low of $20.58.

Analysis

The market is starting to price CPB as a classic value trap: low multiple, but no visible catalyst to stop the numerator from shrinking. The important second-order issue is that a leveraged balance sheet makes any modest earnings miss more damaging than the headline suggests, because equity holders absorb both operating pressure and refinancing optionality risk if the operating trend does not stabilize. In other words, the stock can look statistically cheap for a long time while still underperforming because the debt stack prevents a clean rerating.

The real competitive signal is not just weaker consumer demand, but category share loss versus faster-moving packaged food peers that can trade margin for volume more effectively. If pricing power is fading in snacks and input volatility persists, CPB may be forced into promotions or mix deterioration to defend shelf space, which is typically a multi-quarter issue rather than a one-quarter noise event. That dynamic also raises the risk that distributors and retailers prioritize brands with better velocity, further compressing CPB's negotiating leverage.

The contrarian bull case is that the setup is already so derated that any evidence of stabilization could trigger a sharp short-covering rally, especially if management avoids additional guidance cuts. However, the burden of proof is high: with the stock near long-term lows, a rerating requires either sustained margin recovery or meaningful balance-sheet improvement, neither of which appears likely over the next 1-2 quarters. Until then, the path of least resistance remains lower, but the stock may become tradable on sentiment extremes rather than fundamentals.

Key Decisions for Investors

• Short CPB on rallies over the next 2-6 weeks; risk/reward favors downside continuation if the next catalyst is another guidance reset or weak channel checks, with prior lows acting as a near-term magnet.
• If willing to express via options, buy CPB puts 1-3 months out around the next earnings window; this isolates downside from multiple compression while capping risk if the stock stabilizes on technical bounce.
• Pair trade: short CPB vs long a higher-quality defensive staple with cleaner execution and less leverage (e.g., GIS or KHC) over the next 1-2 quarters; thesis is that the market will reward balance-sheet resilience over cheapness alone.
• Do not buy the dip purely on valuation until there is evidence of volume stabilization and margin inflection; the highest-risk mistake here is treating a low P/E as a catalyst rather than a symptom.